Event time: 事件时间：
Published: 文章发布：
TAKEDA PHARMACEUTICAL CO LTD files 6-K FDA update: FDA Accepts New Drug Application Under Priority ReviewTAKEDA PHARMACEUTICAL CO LTD (TAK) 提交 FDA 相关 6-K 披露：FDA Accepts New Drug Application Under Priority Review
TAKEDA PHARMACEUTICAL CO LTD files 6-K FDA update: FDA Accepts New Drug Application Under Priority Review. The SEC accepted the filing at 2026-09-14T06:25:50-04:00; the stated regulatory fact is: FDA Accepts New Drug Application Under Priority Review.
Source: SEC filing
TAKEDA PHARMACEUTICAL CO LTD (TAK) 提交 FDA 相关 6-K 披露：FDA Accepts New Drug Application Under Priority Review。SEC 于 2026-09-14T06:25:50-04:00 接收该文件；文件明确披露的监管事实为：FDA Accepts New Drug Application Under Priority Review。
来源：SEC 原始文件
For information only. Not investment advice.内容仅供参考，不构成投资建议。